Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Shares Shorted: Short Interest Down 88.8% in October

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a large decrease in short interest in October. As of October 30th, there was short interest totaling 2,140 shares, a decrease of 88.8% from the October 15th total of 19,178 shares. Based on an average trading volume of 241,294 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Analyst Ratings Changes

DSNKY has been the subject of several analyst reports. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Daiichi Sankyo presently has a consensus rating of “Reduce”.

Daiichi Sankyo Trading Down 3.0%

Shares of DSNKY opened at $17.68 on Wednesday. The business has a 50-day moving average of $17.80 and a 200 day moving average of $17.57. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $24.77. The firm has a market cap of $32.94 billion, a P/E ratio of 18.04, a price-to-earnings-growth ratio of 2.08 and a beta of -0.10. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.08. The business had revenue of $3.77 billion for the quarter, compared to analysts’ expectations of $3.58 billion. Daiichi Sankyo had a return on equity of 16.31% and a net margin of 12.13%. As a group, research analysts forecast that Daiichi Sankyo will post 0.87 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).